In a significant stride towards advancing precision medicine, GlaxoSmithKline (GSK) has announced a three-year collaboration agreement with Tempus, a leader in data-driven precision medicine, to get access to Tempus’ AI-enable…
In a significant leap forward in the ongoing battle against drug-resistant cancers, Gradalis, a forefront player in personalized cancer immunotherapy, has unveiled promising results for its innovative candidate, GRAD1405 bi-shRNAi.…
In a groundbreaking development, a team of scientists have discovered a new class of antibiotics using artificial intelligence, marking the first such breakthrough in over six decades. This momentous achievement…
A Strategic Roadmap to Harness the Power of Artificial Intelligence in Medicines Regulation In a bold leap towards innovation, the European Medicines Agency (EMA) and the Heads of Medicines Agencies…
In a strategic move that is set to reshape the landscape of the biopharmaceutical industry, Pfizer has announced its monumental $43 billion acquisition of Seagen. This landmark deal marks a…
In a groundbreaking move to advance cancer therapeutics, AstraZeneca, a global pharmaceutical giant, has recently entered into a strategic collaboration with Absci, a leading synthetic biology company. The deal, valued…
Groundbreaking Gene-Editing Therapy Receives Green Light, Signaling a New Era in Sickle Cell Treatment Date: 12 December 2023 Introduction: In a landmark decision, the U.S. Food and Drug Administration (FDA)…
MHRA Approves CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, Marking a Milestone in Precision Medicine Date: 7 December 2023 Introduction: In a historic move that signals a new…